{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:01:07Z","timestamp":1774512067134,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R43AI127053"],"award-info":[{"award-number":["R43AI127053"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ymthe.2021.05.018","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:23:59Z","timestamp":1622247839000},"page":"2782-2793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus"],"prefix":"10.1016","volume":"29","author":[{"given":"Emily A.","family":"Voigt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Fuerte-Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Van Hoeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.05.018_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2010.10.020","article-title":"mRNA as gene therapeutic: How to control protein expression","volume":"150","author":"Tavernier","year":"2011","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2021.05.018_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2015.986104","article-title":"Lipid-based mRNA vaccine delivery systems","volume":"14","author":"Midoux","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2021.05.018_bib3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/biot.201400387","article-title":"Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology","volume":"10","author":"Rodrigues","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ymthe.2021.05.018_bib4","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing\u2014An overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2021.05.018_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-1-62703-733-4_23","article-title":"Vaccine production: upstream processing with adherent or suspension cell lines","volume":"1104","author":"Genzel","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib6","article-title":"Animal cell expression systems","author":"Butler","year":"2017","journal-title":"Adv. Biochem. Eng. Biotechnol"},{"key":"10.1016\/j.ymthe.2021.05.018_bib7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1080\/21645515.2017.1295191","article-title":"New approaches for characterization of the genetic stability of vaccine cell lines","volume":"13","author":"Ng","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2021.05.018_bib8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2021.05.018_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15585\/mmwr.mm6617e2","article-title":"Addressing a yellow fever vaccine shortage\u2014United States, 2016\u20132017","volume":"66","author":"Gershman","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ymthe.2021.05.018_bib10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: Challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1080\/14760584.2016.1205492","article-title":"Manufacturing DTaP-based combination vaccines: Industrial challenges around essential public health tools","volume":"15","author":"Vidor","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2021.05.018_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/14760584.2015.985662","article-title":"Analytics for vaccine economics and pricing: Insights and observations","volume":"14","author":"Robbins","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2021.05.018_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.biologicals.2010.02.015","article-title":"Human and animal vaccine contaminations","volume":"38","author":"Pastoret","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.ymthe.2021.05.018_bib14","series-title":"Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer","year":"2002"},{"key":"10.1016\/j.ymthe.2021.05.018_bib15","doi-asserted-by":"crossref","first-page":"e92153","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.05.018_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.coviro.2012.02.006","article-title":"Reaching the last one per cent: Progress and challenges in global polio eradication","volume":"2","author":"Kew","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya virus and the global spread of a mosquito-borne disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.05.018_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1874312901610010129","article-title":"A review of Chikungunya virus-induced arthralgia: Clinical manifestations, therapeutics, and pathogenesis","volume":"10","author":"Goupil","year":"2016","journal-title":"Open Rheumatol. J."},{"key":"10.1016\/j.ymthe.2021.05.018_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","article-title":"Development of an attenuated strain of chikungunya virus for use in vaccine production","volume":"4","author":"Levitt","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2021.05.018_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2021.05.018_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4269\/ajtmh.1992.47.98","article-title":"Limited potential for mosquito transmission of a live, attenuated chikungunya virus vaccine","volume":"47","author":"Turell","year":"1992","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2021.05.018_bib22","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","article-title":"Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein","volume":"86","author":"Gorchakov","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.05.018_bib24","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.05.018_bib25","doi-asserted-by":"crossref","first-page":"e2124","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective chikungunya virus-like particle vaccine produced in insect cells","volume":"7","author":"Metz","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib26","doi-asserted-by":"crossref","first-page":"e0004782","DOI":"10.1371\/journal.pntd.0004782","article-title":"Expression and characterization of yeast derived Chikungunya virus like particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate","volume":"10","author":"Saraswat","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib28","doi-asserted-by":"crossref","first-page":"e1002142","DOI":"10.1371\/journal.ppat.1002142","article-title":"Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism","volume":"7","author":"Plante","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2021.05.018_bib29","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","article-title":"Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice","volume":"88","author":"Halleng\u00e4rd","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib30","doi-asserted-by":"crossref","first-page":"e83527","DOI":"10.1172\/jci.insight.83527","article-title":"Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus","volume":"2","author":"Roques","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2021.05.018_bib31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nm.4253","article-title":"A chikungunya fever vaccine utilizing an insect-specific virus platform","volume":"23","author":"Erasmus","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.05.018_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib33","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/infdis\/jiu014","article-title":"Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose","volume":"209","author":"Roy","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib34","doi-asserted-by":"crossref","first-page":"e0004007","DOI":"10.1371\/journal.pntd.0004007","article-title":"Extended preclinical safety, efficacy and stability testing of a live-attenuated Chikungunya vaccine candidate","volume":"9","author":"Plante","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib35","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika","volume":"26","author":"Erasmus","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.05.018_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.omtm.2020.06.011","article-title":"Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection","volume":"18","author":"Erasmus","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"suppl 5","key":"10.1016\/j.ymthe.2021.05.018_bib37","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1093\/infdis\/jiw284","article-title":"Animal models of Chikungunya virus infection and disease","volume":"214","author":"Haese","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib38","first-page":"64","article-title":"Limitations of current in\u00a0vivo mouse models for the study of Chikungunya virus pathogenesis","volume":"3","author":"Chan","year":"2015","journal-title":"Med. Sci. (Basel)"},{"key":"10.1016\/j.ymthe.2021.05.018_bib39","doi-asserted-by":"crossref","first-page":"e1004863","DOI":"10.1371\/journal.ppat.1004863","article-title":"IFIT1 differentially interferes with translation and replication of alphavirus genomes and promotes induction of type I interferon","volume":"11","author":"Reynaud","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2021.05.018_bib40","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.ppat.0040029","article-title":"A mouse model for Chikungunya: Young age and inefficient type-I interferon signaling are risk factors for severe disease","volume":"4","author":"Couderc","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2021.05.018_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/jiw111","article-title":"Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus","volume":"214","author":"Muthumani","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib42","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1016\/j.vaccine.2008.03.060","article-title":"Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus","volume":"26","author":"Muthumani","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2021.05.018_bib43","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1371\/journal.pntd.0000928","article-title":"A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates","volume":"5","author":"Mallilankaraman","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib44","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/infdis\/jiu114","article-title":"DNA vaccine initiates replication of live attenuated chikungunya virus in\u00a0vitro and elicits protective immune response in mice","volume":"209","author":"Tretyakova","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-020-00241-z","article-title":"Engineering a fidelity-variant live-attenuated vaccine for chikungunya virus","volume":"5","author":"Weiss","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2021.05.018_bib46","doi-asserted-by":"crossref","first-page":"e01606-18","DOI":"10.1128\/JVI.01606-18","article-title":"Chikungunya virus fidelity variants exhibit differential attenuation and population diversity in cell culture and adult mice","volume":"93","author":"Riemersma","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2021.05.018_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2016.01.009","article-title":"Next generation sequencing of DNA-launched Chikungunya vaccine virus","volume":"490","author":"Hidajat","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2021.05.018_bib48","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2018.10.033","article-title":"Defining a correlate of protection for chikungunya virus vaccines","volume":"37","author":"Milligan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2021.05.018_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow fever in Angola and beyond\u2014The problem of vaccine supply and demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.05.018_bib50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bjid.2017.02.004","article-title":"Yellow fever outbreak in Brazil, 2017","volume":"21","author":"Goldani","year":"2017","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2021.05.018_bib51","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow fever\u2014Once again on the radar screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.05.018_bib52","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(16)30116-7","article-title":"Yellow fever: A global reckoning","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.05.018_bib53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3201\/eid1305.070015","article-title":"Chikungunya virus in US travelers returning from India, 2006","volume":"13","author":"Lanciotti","year":"2007","journal-title":"Emerg. Infect. Dis."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621003002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621003002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:02:40Z","timestamp":1761501760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621003002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1525001621003002"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.018","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}